Overview

Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer

Status:
Completed

Trial end date:
2019-12-31

Target enrollment:

Participant gender:

Summary

This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of estetrol for the treatment of patients with advanced breast cancer. After completing phase I part of the study (i.e. 4 weeks of treatment), patients will receive further treatment for 8 weeks at their individual phase I dose level (phase IIa part of the study).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pantarhei Oncology B.V.

Treatments:

Estrogens